Eurotechnology Japan KK

What is Eurotechnology Japan KK?

Eurotechnology Japan KK is an angel network-based investment firm situated in Tokyo, Japan, engaging primarily in early-stage and seed funding with an investment range between $100,000 and $500,000. Focused on facilitating Japan market entry for high-tech and pharma ventures, Eurotechnology Japan KK partners with companies to drive innovation and growth within the local context. Since its foundation in 1997, the firm has amassed expertise in a variety of business sectors, specializing in mergers and acquisitions (M&A), building business strategies for Japan, and aiding in company turnarounds.

They have a notable track record in working with international ventures, especially from the European and US markets, to navigate the complex Japanese market landscape. The firm applies science-based methodologies, leveraging diligence in semiconductor physics, data science, statistics, and mathematics, to inform their investment thesis and business development strategies. Eurotechnology Japan KK offers professional services spanning the pharmaceutical industry, medical devices, financial industry, technology industries, and energy sector with a focus on renewable sources.

Additionally, they handle cross-border transactions and corporate governance, emphasizing the importance of managing post-merger integration and corporate relationships. The firm also contributes to market research and market entry strategies for companies looking to penetrate or revitalize their presence in the Japanese market.

The comprehensive suite of services aims to meet the needs of a diverse client range, from ventures to leading multinationals.

The firm's founder, Gerhard Fasol, brings a strong academic background with experience at Cambridge University and significant contributions to various scientific and leadership communities, demonstrating a keen understanding of the intersection between innovation, strategy, and transnational business development.

What they say:

We invest in Japan market entry by high-tech and pharma ventures, and selected local projects here in Japan, most driven by us in cooperation with partners.